• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于细胞疗法中生物标志物发现与验证的全转录组分析。

Global transcriptional analysis for biomarker discovery and validation in cellular therapies.

作者信息

Stroncek David F, Jin Ping, Wang Ena, Ren Jiagiang, Sabatino Marianna, Marincola Francesco M

机构信息

Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

Mol Diagn Ther. 2009;13(3):181-93. doi: 10.2165/01250444-200913030-00003.

DOI:10.2165/01250444-200913030-00003
PMID:19650671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2949270/
Abstract

Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biologic activity that is linked to a relevant biologic property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such as flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of non-coding microRNA (miRNA), which plays an important role in cellular development, differentiation, metabolism, and signal transduction, can distinguish between different types of stem cells and leukocytes. Both gene and miRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and miRNA expression microarrays in potency testing of cellular therapies are discussed.

摘要

效力测试是细胞治疗产品评估的重要组成部分。效力测定是对与相关生物学特性相关联的产品特异性生物活性的定量测量,理想情况下,也是对产品体内作用机制的定量测量。体内和体外测定均可用于效力测试。由于从生产完成到从实验室放行以供患者使用之间的时间通常有限,因此通常使用体外测定,如流式细胞术、酶联免疫吸附测定(ELISA)和细胞毒性测定。需要更好的效力测定方法来评估细胞治疗产品复杂多样的功能,其中一些功能尚未完全了解。使用微阵列技术的基因表达谱分析已被广泛有效地用于评估细胞对刺激的反应变化以及癌症分类。初步研究表明,在细胞发育、分化、代谢和信号转导中起重要作用的非编码微小RNA(miRNA)的表达可以区分不同类型的干细胞和白细胞。基因和miRNA表达谱分析都有可能成为测试细胞治疗效力的重要工具。本文将讨论效力测试、细胞治疗效力测试相关的复杂性以及基因和miRNA表达微阵列在细胞治疗效力测试中的潜在作用。

相似文献

1
Global transcriptional analysis for biomarker discovery and validation in cellular therapies.用于细胞疗法中生物标志物发现与验证的全转录组分析。
Mol Diagn Ther. 2009;13(3):181-93. doi: 10.2165/01250444-200913030-00003.
2
Potency analysis of cellular therapies: the emerging role of molecular assays.细胞疗法的效力分析:分子检测的新兴作用
J Transl Med. 2007 May 30;5:24. doi: 10.1186/1479-5876-5-24.
3
Qualification of a flow cytometry-based method for the evaluation of cytotoxicity of GTA002 natural killer cell therapy.一种基于流式细胞术的方法用于评估GTA002自然杀伤细胞疗法细胞毒性的鉴定
Heliyon. 2024 Jan 17;10(2):e24715. doi: 10.1016/j.heliyon.2024.e24715. eCollection 2024 Jan 30.
4
Quality assessment of cellular therapies: the emerging role of molecular assays.细胞疗法的质量评估:分子检测的新兴作用
Korean J Hematol. 2010 Mar;45(1):14-22. doi: 10.5045/kjh.2010.45.1.14. Epub 2010 Mar 31.
5
Potency testing of cell and gene therapy products.细胞和基因治疗产品的效价检测
Front Med (Lausanne). 2023 May 5;10:1190016. doi: 10.3389/fmed.2023.1190016. eCollection 2023.
6
Microarray-based gene expression analysis as a process characterization tool to establish comparability of complex biological products: scale-up of a whole-cell immunotherapy product.基于微阵列的基因表达分析作为一种过程表征工具,用于建立复杂生物制品的可比性:全细胞免疫治疗产品的放大生产
Biotechnol Bioeng. 2009 Nov 1;104(4):796-808. doi: 10.1002/bit.22441.
7
Skin sensitizers differentially regulate signaling pathways in MUTZ-3 cells in relation to their individual potency.皮肤致敏剂根据其各自的效力差异调节MUTZ-3细胞中的信号通路。
BMC Pharmacol Toxicol. 2014 Feb 11;15:5. doi: 10.1186/2050-6511-15-5.
8
Using miRNA-mRNA Interaction Analysis to Link Biologically Relevant miRNAs to Stem Cell Identity Testing for Next-Generation Culturing Development.利用miRNA- mRNA相互作用分析将生物学相关的miRNA与用于下一代培养发展的干细胞身份测试相联系。
Stem Cells Transl Med. 2016 Jun;5(6):709-22. doi: 10.5966/sctm.2015-0154. Epub 2016 Apr 13.
9
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.国际细胞治疗协会关于间充质基质细胞免疫功能测定作为晚期临床试验效力释放标准的观点。
Cytotherapy. 2016 Feb;18(2):151-9. doi: 10.1016/j.jcyt.2015.11.008. Epub 2015 Dec 23.
10
Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry.细胞治疗产品效价测定方法的开发:ISCT 对行业要求和经验的综述。
Cytotherapy. 2013 Jan;15(1):9-19. doi: 10.1016/j.jcyt.2012.10.008.

引用本文的文献

1
Biomarkers in T cell therapy clinical trials.T 细胞治疗临床试验中的生物标志物。
J Transl Med. 2011 Aug 19;9:138. doi: 10.1186/1479-5876-9-138.
2
Superparamagnetic iron oxide nanoparticles labeling of bone marrow stromal (mesenchymal) cells does not affect their "stemness".超顺磁性氧化铁纳米颗粒标记骨髓基质(间充质)细胞不会影响其“干性”。
PLoS One. 2010 Jul 7;5(7):e11462. doi: 10.1371/journal.pone.0011462.

本文引用的文献

1
Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.普乐沙福(AMD3100)和粒细胞集落刺激因子(G-CSF)基于整体基因和微小RNA表达特征动员不同的CD34+细胞群体。
Blood. 2009 Sep 17;114(12):2530-41. doi: 10.1182/blood-2009-04-214403. Epub 2009 Jul 14.
2
Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool.间充质干细胞及其作为细胞替代疗法和疾病建模工具的应用。
J Cell Mol Med. 2008 Dec;12(6B):2552-65. doi: 10.1111/j.1582-4934.2008.00516.x.
3
Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.用于TCR基因治疗的外周血淋巴细胞的临床规模慢病毒载体转导及在低分化细胞中表达的潜力。
J Immunother. 2008 Nov-Dec;31(9):830-9. doi: 10.1097/CJI.0b013e31818817c5.
4
Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis.通过微小RNA和互补DNA表达分析鉴别两种动员的外周血干细胞
J Transl Med. 2008 Jul 22;6:39. doi: 10.1186/1479-5876-6-39.
5
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.间充质干细胞治疗类固醇难治性重度急性移植物抗宿主病:一项II期研究。
Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.
6
Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells.对外周血单个核细胞制备的未成熟树突状细胞的基因表达谱进行评估。
Transfusion. 2008 Apr;48(4):647-57. doi: 10.1111/j.1537-2995.2007.01615.x. Epub 2008 Feb 12.
7
Immunomodulation by mesenchymal stem cells and clinical experience.间充质干细胞的免疫调节作用及临床经验
J Intern Med. 2007 Nov;262(5):509-25. doi: 10.1111/j.1365-2796.2007.01844.x.
8
Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.与粒细胞集落刺激因子动员的来自同一供体的细胞相比,AMD3100快速动员的人祖细胞能以更高的频率重新填充NOD/SCID小鼠。
Biol Blood Marrow Transplant. 2007 Apr;13(4):398-411. doi: 10.1016/j.bbmt.2006.12.445.
9
Dendritic cell vaccines for leukemia patients.用于白血病患者的树突状细胞疫苗。
Expert Rev Anticancer Ther. 2007 Mar;7(3):275-83. doi: 10.1586/14737140.7.3.275.
10
Gene expression profiling of cutaneous wound healing.皮肤伤口愈合的基因表达谱分析。
J Transl Med. 2007 Feb 21;5:11. doi: 10.1186/1479-5876-5-11.